Annual report
4188.TEDINET S100W27P
Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amended by S100WZVZ (2025-11-12).
Key figures · 160
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.41T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.39T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.63T | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.98T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.26T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥196.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥261.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥150.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥240.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥168.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥290.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥32.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥45.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥119.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥96.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥177.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥7.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥105.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥178.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥135.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥209.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥22.7bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥5.89T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥6.10T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥5.77T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.57T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.29T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥3.61T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥3.83T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.28T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.28T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.99T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.74T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.76T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.56T | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.46T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.24T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥326.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥294.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥297.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥245.8bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥349.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥552.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥465.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥355.2bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥346.9bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥467.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥275.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥246.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥247.6bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥128.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥217.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥246.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥241.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥336.3bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥142.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥31.64 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥84.07 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥67.85 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥124.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-5.32 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥31.63 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥80.77 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥64.99 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥115.03 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-5.32 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,223.01 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,239.61 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,100.27 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,026.03 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥870.4 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 29.5% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.9% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.1% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 23.4% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 2.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -0.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 63,258 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 66,358 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 68,639 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 69,784 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 69,607 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥75.8bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥212.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥125.3bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥69.5bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥24.7bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥55.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥190.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥51.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥186.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥103.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥52.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.4bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥51.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥189.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥137.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥188.8bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥104.5bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥56.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥11.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.97T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.99T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.01T | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.80T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.99T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.27T | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.38T | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥706.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥614.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥471.4bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥409.7bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥392.3bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥22.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥26.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥96.73 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.74 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.51 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.56 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.37 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥96.71 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥127.46 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥70.41 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.62 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.87 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥32 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥496.53 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥431.67 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.8 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥286.54 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥273.62 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 34.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,506,288,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 414 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 501 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 430 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 223 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 201 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 6257 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥335.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥190.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥145.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥253.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥13.4bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥211.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥211.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥358.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥11.4bn |
| Basic Materials And Polymersreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥46.8bn |
| Basic Materials And Polymersreportable segment | employees | at 2025-03-31 | 6572 pure |
| Basic Materials And Polymersreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.01T |
| Basic Materials And Polymersreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥972.4bn |
| Basic Materials And Polymersreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥34.8bn |
| Basic Materials And Polymersreportable segment | segment assets | at 2025-03-31 | ¥704.4bn |
| Basic Materials And Polymersreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥15.6bn |
| Industrial Gasesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥142.4bn |
| Industrial Gasesreportable segment | employees | at 2025-03-31 | 19762 pure |
| Industrial Gasesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.31T |
| Industrial Gasesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.30T |
| Industrial Gasesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Industrial Gasesreportable segment | segment assets | at 2025-03-31 | ¥2.46T |
| Industrial Gasesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥186.1bn |
| MMA And Derivativesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥23.4bn |
| MMA And Derivativesreportable segment | employees | at 2025-03-31 | 3995 pure |
| MMA And Derivativesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥416.4bn |
| MMA And Derivativesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥402.1bn |
| MMA And Derivativesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥14.3bn |
| MMA And Derivativesreportable segment | segment assets | at 2025-03-31 | ¥529.2bn |
| MMA And Derivativesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥35.3bn |
| Pharmareportable segment | capex | 2024-04-01 → 2025-03-31 | ¥7.9bn |
| Pharmareportable segment | employees | at 2025-03-31 | 4490 pure |
| Pharmareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥460.4bn |
| Pharmareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥460.3bn |
| Pharmareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥92m |
| Pharmareportable segment | segment assets | at 2025-03-31 | ¥963.0bn |
| Pharmareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥65.4bn |
| Specialty Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥114.6bn |
| Specialty Materialsreportable segment | employees | at 2025-03-31 | 21260 pure |
| Specialty Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.09T |
| Specialty Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.08T |
| Specialty Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.3bn |
| Specialty Materialsreportable segment | segment assets | at 2025-03-31 | ¥1.34T |
| Specialty Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥354.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥204.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥149.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥274.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥13.6bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥220.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥220.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥398.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥12.4bn |
| Basic Materials And Polymersreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥39.2bn |
| Basic Materials And Polymersreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Basic Materials And Polymersreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.11T |
| Basic Materials And Polymersreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥39.0bn |
| Basic Materials And Polymersreportable segment | segment assets | at 2024-03-31 | ¥858.9bn |
| Basic Materials And Polymersreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥25.4bn |
| Industrial Gasesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥126.3bn |
| Industrial Gasesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.26T |
| Industrial Gasesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.25T |
| Industrial Gasesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Industrial Gasesreportable segment | segment assets | at 2024-03-31 | ¥2.45T |
| Industrial Gasesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥163.0bn |
| MMA And Derivativesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25.0bn |
| MMA And Derivativesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥361.8bn |
| MMA And Derivativesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥347.9bn |
| MMA And Derivativesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13.9bn |
| MMA And Derivativesreportable segment | segment assets | at 2024-03-31 | ¥590.2bn |
| MMA And Derivativesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.5bn |
| Pharmareportable segment | capex | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Pharmareportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥437.4bn |
| Pharmareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥437.2bn |
| Pharmareportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥138m |
| Pharmareportable segment | segment assets | at 2024-03-31 | ¥933.6bn |
| Pharmareportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥56.3bn |
| Specialty Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥80.9bn |
| Specialty Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.05T |
| Specialty Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.04T |
| Specialty Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| Specialty Materialsreportable segment | segment assets | at 2024-03-31 | ¥1.39T |
| Specialty Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,436
| Item | Context | Value | Unit |
|---|---|---|---|
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row21Member | 0.785 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row21Member | 0.791 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row21Member | 0.749 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 14369000 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 14026000 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 6685000 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 6727000 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 7685000 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 7299000 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 80 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 70 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 85 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 78 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 40 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 29 | |
| Research and development expenses research and development activities | CurrentYearDuration | 123900000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00808-000SpecialtyMaterialsReportableSegmentMember | 25700000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00808-000MMAAndDerivativesReportableSegmentMember | 6800000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00808-000BasicMaterialsAndPolymersReportableSegmentMember | 8600000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00808-000PharmaReportableSegmentMember | 66500000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00808-000IndustrialGasesReportableSegmentMember | 5000000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 300000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_jpcrp030000-asr_E00808-000SpecialtyMaterialsReportableSegmentMember | 80867000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00808-000SpecialtyMaterialsReportableSegmentMember | 114603000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_jpcrp030000-asr_E00808-000MMAAndDerivativesReportableSegmentMember | 24965000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00808-000MMAAndDerivativesReportableSegmentMember | 23355000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_jpcrp030000-asr_E00808-000BasicMaterialsAndPolymersReportableSegmentMember | 39170000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00808-000BasicMaterialsAndPolymersReportableSegmentMember | 46750000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_jpcrp030000-asr_E00808-000PharmaReportableSegmentMember | 5129000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00808-000PharmaReportableSegmentMember | 7920000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_jpcrp030000-asr_E00808-000IndustrialGasesReportableSegmentMember | 126257000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00808-000IndustrialGasesReportableSegmentMember | 142427000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4417000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2243000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration_CorporateSharedMember | 3069000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 1929000000 | JPY |
| Capital expenditures overview of capital expenditures etc | Prior1YearDuration | 283874000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 339227000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 1506288107 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 1506288107 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 1506288107 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 1506288107 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 2 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 158 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 86 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 1903 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 797 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 527 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 290010 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |